Aug. 22, 2017 – In the wake of an FDA study showing that consumers recall risk information better when they are not inundated with a comprehensive list of risks in direct-to-consumer (DTC) ads, the agency is establishing a public docket “to assist with its development of recommendations” in this area. The FDA’s Office of Prescription […]
Read more
Aug. 7, 2017 – In a 94-1 vote, the U.S. Senate on Aug. 3 passed FDA user fee reauthorization legislation that will revise and extend the user fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products through 2022. H.R. 2430, the FDA Reauthorization Act of 2017, was passed by the House […]
Read more July 25, 2017 – A large majority of Americans recognize the value of the information provided in direct-to-consumer (DTC) ads and state that the ads promote adherence and help patients remember to visit their doctor, according to a recent survey of 1,500 people sponsored by the Pharmaceutical Research and Manufacturers of America (PhRMA) and conducted […]
Read more